Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistim ASAFRA:MD1 98 Debt-to-EBITDA is 0.15 as of Mar. 2026, which is 17% below its 10-year median of 0.18. GuruFocus rates FRA:MD1 with a GF Score™ of 98/100 and a GF Value™ of €23.26 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 472 Medical Devices & Instruments companies, Medistim ASA ranks better than 86.23% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medistim ASA's Debt-to-EBITDA or its related term are showing as below:
FRA:MD1'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09 Med: 0.18 Max: 0.34
Current: 0.16
During the past 13 years, the highest Debt-to-EBITDA Ratio of Medistim ASA was 0.34. The lowest was 0.09. And the median was 0.18.
FRA:MD1's Debt-to-EBITDA is ranked better than 86.23% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs FRA:MD1: 0.16
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medistim ASA Debt-to-EBITDA Related Terms
Medistim ASA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Medistim ASA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MD1 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Medistim ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medistim ASA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Medistim ASA (FRA:MD1) has a Debt-to-EBITDA of 0.15 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medistim ASA. This is 17% below median its historical median of 0.18. Over the past decade, Medistim ASA's Debt-to-EBITDA has ranged from 0.09 to 0.34. According to the industry distribution chart, Medistim ASA ranks #65 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is Medistim ASA's Debt-to-EBITDA too high?
Medistim ASA's current Debt-to-EBITDA of 0.15 is 17% below median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.34. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Medistim ASA's value of 0.15 is 90.9% below this industry median. Based on the distribution chart, Medistim ASA ranks #65 out of 472 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #65 out of 472 companies for Debt-to-EBITDA. This places Medistim ASA in the top 14% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. Medistim ASA's value of 0.15 is 90.9% below this benchmark. Historically, Medistim ASA's own Debt-to-EBITDA has ranged from 0.09 to 0.34 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 1.64, Medistim ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current Debt-to-EBITDA of 0.15 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medistim ASA. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current Debt-to-EBITDA is 0.15, which is 17% below median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Modestly Undervalued. The stock's GF Value™ is €23.26, compared to a current price of €20.40 — trading 12.3% below its estimated fair value. The current Debt-to-EBITDA is 0.15, which is 17% below median its 10-year median of 0.18 and 90.9% below the Medical Devices & Instruments industry median of 1.64. Medistim ASA's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current Debt-to-EBITDA is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (FRA:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €20.40 is trading 12.3% below its estimated GF Value™ of €23.26.
GuruFocus considers Medistim ASA to be Modestly Undervalued.
Key valuation signals for FRA:MD1:
Debt-to-EBITDA: 0.15 (17% below median its 10-year median of 0.18)
GF Value™: €23.26 vs. price of €20.40 (12.3% below fair value)
Industry Position: 90.9% below the Medical Devices & Instruments median (#65 of 472)
No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
98GF Score
Get the complete analysis for FRA:MD1
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MD1 has been successfully added to your 
